Home » ISPE Updates and Expands Guidance for Testing of GxP Systems
ISPE Updates and Expands Guidance for Testing of GxP Systems
ISPE, a leading authority on best practices for the pharmaceutical industry, announced on Jan. 16 that it has issued updated and expanded guidance to help pharmaceutical companies maximize testing efficiency of computerized and software-based systems that impact patient safety, product quality and data integrity. The second edition of the GAMP Testing Guide has been revised to conform with GAMP 5 concepts and terminology and reflect ICH Q8, Q9 and Q10, Quality by Design and Process Analytical Technology principles. It has also been expanded to include information on cloud computing, automated testing and non-linear development.
“We have aimed this Guide at anyone who has ever worried that their testing is not sufficiently focused on the real risks to patient safety or wondered whether they might be doing too much or too little testing,” said Karen Ashworth, who co-led the industry group responsible for producing the guidance. “The Guide offers practical advice on how to use risk assessment to define the correct scope of testing and on how to avoid costly duplication of testing that has already been done by a supplier or at an earlier phase of the system lifecycle.”
The ISPE GAMP Good Practice Guide: A Risk-Based Approach to Testing of GxP Systems (Second Edition) encourages regulated pharmaceutical companies and their suppliers to work together to ensure sufficient test coverage to prove that systems are fit for their intended use and minimize duplicated effort. The Guide provides answers as to which system elements should be tested, why they should be tested, how much testing is necessary and how tests should be conducted and documented.
The ISPE GAMP Good Practice Guide: A Risk-Based Approach to Testing of GxP Systems (Second Edition) is available for purchase on the ISPE website.
Merck Stops Development of Parkinson’s DrugFrom Bloomberg
Merck & Co. will end development of preladenant because a preliminary review of late-stage clinical trials suggests it doesn’t work
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
- All news »